Lansoprazol "viatris"

Lansoprazole, the active ingredient in Lansoprazol viatris, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens, and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Lansoprazol viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by lowering gastric acidity. - Helicobacter pylori eradication regimens: enhances antibiotic effectiveness by creating a less acidic environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Lansoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation: occasional. - Dry mouth.

Serious or Rare Side Effects: - Severe allergic reactions (e.g., Stevens‑Johnson syndrome, anaphylaxis). - Acute interstitial nephritis. - Clostridioides difficile‑associated diarrhea. - Low magnesium levels (hypomagnesemia) with prolonged use. - Bone fractures with long‑term therapy. - Liver enzyme elevations.

Before prescribing Lansoprazole, consider the following safety measures. - Assess renal and hepatic function: adjust therapy if severe impairment is present. - Review concomitant medications: avoid drugs that require gastric acidity for absorption. - Monitor long‑term users: watch for magnesium deficiency, bone health, and potential infections. - Pregnancy and lactation: use only if the potential benefit outweighs risk; discuss with a healthcare professional. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption leading to therapeutic failure. - Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability. - Clopidogrel: diminished activation, potentially reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Methotrexate (high dose): reduced renal clearance; watch for toxicity. - Digoxin: modest increase in serum levels; consider dose adjustment. - Diazepam: increased plasma concentration; monitor for sedation.